A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor-Positive Advanced or Metastatic Breast Cancer
Latest Information Update: 13 Jun 2022
At a glance
- Drugs Fulvestrant (Primary) ; Vistusertib (Primary) ; Everolimus
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MANTA
- 11 Jun 2022 This trial has been discontinued in France according to European Clinical Trials Database record.
- 10 Mar 2022 This trial has been completed in Spain (End Date: 31 Dec 2021), according to European Clinical Trials Database record.
- 16 Feb 2022 This trial has been discontinued in Germany (Global end date: 31 Dec 2021).